SCHEMBL6779924

SCHEMBL6779924

C#CCNC(=O)N1CC(c2ccc(C(F)(F)F)cc2)C1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.43
CHRM5 P08912 1/20 0.43
CHRM1 P11229 1/20 0.43
CHRM3 P20309 1/20 0.43
PROKR1 Q8TCW9 2/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 2/20 0.42
F2R P25116 3/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
PAX8 Q06710 2/20 0.41
TACR1 P25103 2/20 0.41
RORC P51449 1/20 0.41
NAMPT P43490 2/20 0.40
TACR3 P29371 1/20 0.40
SLC6A9 P48067 1/20 0.39
KCNH2 Q12809 1/20 0.39
RBP4 P02753 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6774253 0.88 ACACB (0.43) ALDH1A1MEN1KMT2ARORCNAMPT
SCHEMBL6780159 0.85 GRIN2B (0.47) MEN1KMT2ANAMPT
SCHEMBL6778327 0.85 NPC1 (0.46) ALDH1A1MAPTPAX8TACR1RORC
SCHEMBL6783635 0.83 MAPT (0.42) PROKR1MAPTNAMPT
SCHEMBL9596881 0.81 KCNH2 (0.47) KCNH2
SCHEMBL6778334 0.81 TACR1 (0.45) CHRM2CHRM5CHRM1CHRM3PROKR1
SCHEMBL6778331 0.81 TACR1 (0.45) CHRM2CHRM5CHRM1CHRM3PROKR1
SCHEMBL6783908 0.81 TACR1 (0.45) CHRM2CHRM5CHRM1CHRM3PROKR1
SCHEMBL6780786 0.77 LMNA (0.44) MEN1MAPTKMT2AKCNH2
SCHEMBL640772 0.74 F2R (0.43) CHRM2CHRM5CHRM1CHRM3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831078-B1 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant VERNALIS RESEARCH LIMITED (GB) 2004-12-14 US claimed
EP-1049670-B1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RES LTD (GB) 2002-07-17 EP claimed
EP-1049670-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 2000-11-08 EP claimed
WO-1999037613-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 1999-07-29 WO claimed
US-6831078-B1 3-aryl substituted having halo or alkylhalo groups; anxiety, epilepsy; presurgery muscle relaxant VERNALIS RESEARCH LIMITED (GB) 2004-12-14 US disclosed
EP-1049670-B1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RES LTD (GB) 2002-07-17 EP disclosed
EP-1196165-A2 AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES VERNALIS RESEARCH LIMITED (GB) 2002-04-17 EP disclosed
WO-2001007022-A2 AZETIDINE COMPOUNDS IN CNS AND EYE DISEASES VERNALIS RESEARCH LIMITED (GB) 2001-02-01 WO disclosed
EP-1049670-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 2000-11-08 EP disclosed
WO-1999037613-A1 AZETIDINECARBOXAMIDE DERIVATIVES FOR TREATING CNS DISORDERS VERNALIS RESEARCH LIMITED (GB) 1999-07-29 WO disclosed